DELRAY BEACH, Fla., June 21, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today the launch of its Multiplex BioThreat Assay ("MBA"), the first commercially available MBA for the detection of up to six bio-threat organisms on the Centers for Disease Control Category A and B lists. The MBA was developed by MicroFluidic Systems ("MFS"), which was acquired on May 23, 2011, and is a wholly owned subsidiary of PositiveID. The Company plans to initially target public health and university labs that test for pathogens.
